[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 132
Citations 0
Observation
September 21, 2016

Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin

Author Affiliations
  • 1Department of Pathology, City of Hope, Duarte, California
  • 2Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California
  • 3Division of Cytogenetics, City of Hope, Duarte, California
  • 4Department of Surgery, Division of Dermatology, City of Hope, Duarte, California
JAMA Dermatol. Published online September 21, 2016. doi:10.1001/jamadermatol.2016.3117

Primary cutaneous gamma-delta T-cell lymphoma (GD-TCL) is a rare skin lymphoma with numerous clinical presentations. Cytotoxic features on histologic analysis and the T-cell receptor (TCR)-gamma expression on immunohistochemical analysis are clues that should raise suspicion for the diagnosis. Expression of CD30 can also be seen in some cases and should be evaluated because it allows for patients to be treated with brentuximab, as in the present case.

A man in his 40s presented with numerous partially ulcerated papules and small plaques on the trunk (Figure 1A) and extremities covering 35% of the total body surface area without peripheral lymphadenopathy. He also reported severe pruritus and weight loss of 10 pounds over the previous 6 months.

First Page Preview View Large
First page PDF preview
First page PDF preview
×